Cellectar Biosciences Inc
(NAS:CLRB)
$
2.851
-0.009 (-0.31%)
Market Cap: 102.17 Mil
Enterprise Value: 80.48 Mil
PE Ratio: 0
PB Ratio: 10.56
GF Score: 38/100 - Q1 2024 Cellectar Biosciences Inc Earnings Call TranscriptMay 14, 2024$3.18 (+3.92%)Earnings
- Q4 2023 Cellectar Biosciences Inc Earnings Call TranscriptMar 27, 2024$3.64 (-5.58%)Earnings
- Cellectar Biosciences Inc KOL Call TranscriptJan 19, 2024
- Cellectar Biosciences Inc at EBD Group Biotech Showcase TranscriptJan 09, 2024
- Cellectar Biosciences Inc Top-line Data Call TranscriptJan 08, 2024
- Q3 2023 Cellectar Biosciences Inc Earnings Call TranscriptNov 02, 2023$2.4 (+0.84%)Earnings
- Cellectar Biosciences Inc Annual Shareholders Meeting TranscriptJun 23, 2023
- Cellectar Biosciences Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 14, 2023
- Cellectar Biosciences Inc at ROTH Conference TranscriptMar 13, 2023
- Cellectar Biosciences Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) TranscriptSep 20, 2021
- Cellectar Biosciences Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- Cellectar Biosciences Inc at Next Generation Targeted Cancer Therapies - The Cellectar Story! TranscriptOct 16, 2020
Cellectar Biosciences Inc at ROTH Conference Transcript
Mar 13, 2023 / 12:30PM GMT
Release Date Price:
$1.56
(-3.11%)
Jonathan Aschoff
ROTH Capital Partners - Analyst
With me now, we have Jim Caruso, the CEO of Cellectar Biosciences. Welcome, Jim.
Jim Caruso
Cellectar Biosciences, Inc. - President, CEO, & Director
It's a pleasure to be here, Jonathan. And thank you to all of you for attending this session, very much appreciate it.
Questions & Answers
Jonathan Aschoff
ROTH Capital Partners - Analyst
It's great to have you here. So what prompted you to target a pivotal trial in Waldenstrom's macroglobulinemia -- that's a big mouthful; we'll call it WM -- with your lead drug, iopofosine?
Jim Caruso
Cellectar Biosciences, Inc. - President, CEO, & Director
Now that's a great place for us to start. We were in the midst of a Phase 2 trial and a basket study for non-Hodgkin's lymphomas. And we came across a really interesting signal with WM. In fact, of the first six patients that we dosed with iopofosine I 131, we had a 100% response rate.
In fact, the very
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)